Tango Therapeutics Inc (TNGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tango Therapeutics Inc (TNGX) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.72 Million) by net assets ($346.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tango Therapeutics Inc (TNGX) net asset quality to measure how much of total assets are equity-financed.
Tango Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tango Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TNGX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Tango Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tango Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bilfinger SE
XETRA:GBF
|
0.082x |
|
CECEP Wind-Power Corp Co Ltd
SHG:601016
|
0.092x |
|
Constellium Nv
NYSE:CSTM
|
0.227x |
|
Western Gold Co Ltd
SHG:601069
|
-0.159x |
|
Grupa KĘTY SA
WAR:KTY
|
0.134x |
|
Wistron NeWeb Corp
TW:6285
|
-0.097x |
|
Power Integrations Inc
NASDAQ:POWI
|
0.030x |
|
Hoegh Autoliners ASA
OL:HAUTO
|
0.458x |
Annual Cash Flow Conversion Efficiency for Tango Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tango Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Tango Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $346.18 Million | $-138.89 Million | -0.401x | +39.13% |
| 2024-12-31 | $199.52 Million | $-131.50 Million | -0.659x | -41.40% |
| 2023-12-31 | $253.11 Million | $-117.98 Million | -0.466x | -6.61% |
| 2022-12-31 | $249.48 Million | $-109.08 Million | -0.437x | -153.22% |
| 2021-12-31 | $344.75 Million | $-59.53 Million | -0.173x | -109.51% |
| 2020-12-31 | $38.60 Million | $70.07 Million | 1.815x | +157.86% |
| 2019-12-31 | $7.91 Million | $-24.80 Million | -3.138x | -- |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more